^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Excerpt:
TAFINLAR is indicated, in combination with trametinib, for...the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
Source:
Title:
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
Published date:
08/16/2020
Excerpt:
Patients received dabrafenib 150 mg twice per day and trametinib 2 mg per day continuously until disease progression or intolerable toxicity....The confirmed ORR was 38% (90% CI, 22.9% to 54.9%) with P < .0001 against a null rate of 5%, and PFS was 11.4 months (90% CI, 8.4 to 16.3 months);...
DOI:
10.1200/JCO.20.00762
Trial ID:
Source:
Title:
Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring BRAF V600E Mutation
Published date:
11/11/2022
Excerpt:
A 67-year-old Japanese male never-smoker was diagnosed with stage IA3 lung adenocarcinoma….An Oncomine Dx target test of the resected specimen was positive for the BRAF V600E mutation. He was started on dabrafenib 150 mg twice per day and trametinib 2 mg once per day. He had a good clinical response to dabrafenib/trametinib therapy with resolution of abdominal distention. He continued dabrafenib/trametinib treatment without disease progression for 7 months, with no severe adverse effects.
DOI:
https://doi.org/10.2147/OTT.S375246
Source:
Title:
Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma
Published date:
08/30/2021
Excerpt:
Combination of BRAF-specific inhibitor dabrafenib and mitogen-activated protein kinase kinase (MEK) inhibitor trametinib is the standard treatment for BRAF V600E-mutated lung cancer. We report a case of BRAF V600E-mutated lung adenocarcinoma, which presented with respiratory distress due to deterioration of advanced cancer. The tumour responded rapidly and significantly to BRAF/MEK inhibitors, and the patient's symptoms improved within 2 weeks. BRAF/MEK inhibitors are effective treatment in BRAF-mutated lung cancer even under critical conditions.
DOI:
10.1002/rcr2.841
Source:
Title:
Successful re-challenge of dabrafenib-trametinib combination therapy in advanced BRAF V600E-mutant non-small cell lung cancer after previous cytotoxic chemotherapy, targeted therapy, and immunotherapy: a case report
Excerpt:
A 58-year-old Chinese woman with a history of smoking and hypertension was diagnosed with stage IV B lung adenocarcinoma with metastasis. The targeted next-generation sequencing (NGS) of the patient's lung tumor biopsy tissues revealed the presence of a BRAF V600E mutation...At the 4th line, she subsequently re-challenged D/T, and achieved a 4th PR, lasting for 5 months.
DOI:
10.21037/atm-22-3887
Source:
Title:
Response of BRAFV600E-Mutant Lung Adenocarcinoma With Brain Metastasis and Leptomeningeal Dissemination to Dabrafenib Plus Trametinib Treatment
Excerpt:
A 69-year-old Japanese man with a history of cigarette smoking presenting...Pathology results revealed adenocarcinoma with BRAFV600E mutation at pathologic stage T2bN2M0…Subsequently, he was treated with dabrafenib (300 mg/day) along with trametinib (2 mg/day)...The patient continued to receive dabrafenib plus trametinib for 3 months with good response and tolerance.
DOI:
10.1016/j.jtho.2018.12.027
